Status:
COMPLETED
Pharmacokinetics of Voriconazole in Adult ECMO Patients
Lead Sponsor:
University Hospitals, Leicester
Conditions:
Aspergillosis
Influenza
Eligibility:
All Genders
18+ years
Brief Summary
Given the high burden of fungal co-infection in patients admitted to ICU and improved outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of anti-fungal are optimum to...
Detailed Description
A single centre, open label, prospective, observational, pharmacokinetic study of voriconazole administered to adults (aged \> 18 years) supported on ECMO. This is a low-interventional study. There wi...
Eligibility Criteria
Inclusion
- Adults aged ≥18 years
- Admitted to ICU on ECMO support
- Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen.
- Positive invasive aspergillosis infection (positive Aspergillus species culture from respiratory specimen or positive serum galactomannan) or strong clinical suspicion of invasive aspergillosis infection based on symptoms, CT, CXR.
Exclusion
- No participants \< 18 years of age
- Not requiring ECMO support
- No positive influenza or SARS-CoV-2 results
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Key Trial Info
Start Date :
August 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04868188
Start Date
August 10 2021
End Date
May 31 2025
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Leicester
Leicester, United Kingdom